258 related articles for article (PubMed ID: 36208274)
21.
Teng F; Tang W; Wuniqiemu T; Qin J; Zhou Y; Huang X; Wang S; Zhu X; Tang Z; Yi L; Wei Y; Dong J
Front Immunol; 2021; 12():740571. PubMed ID: 34737744
[TBL] [Abstract][Full Text] [Related]
22. m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation.
Ma H; Shen L; Yang H; Gong H; Du X; Li J
IUBMB Life; 2021 Jan; 73(1):108-117. PubMed ID: 33205540
[TBL] [Abstract][Full Text] [Related]
23. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
24. Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases.
You Y; Fu Y; Huang M; Shen D; Zhao B; Liu H; Zheng Y; Huang L
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628623
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of RNA modification N6-methyladenosine in human cancer.
Zhou Z; Lv J; Yu H; Han J; Yang X; Feng D; Wu Q; Yuan B; Lu Q; Yang H
Mol Cancer; 2020 Jun; 19(1):104. PubMed ID: 32513173
[TBL] [Abstract][Full Text] [Related]
26. m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism.
Yue SW; Liu HL; Su HF; Luo C; Liang HF; Zhang BX; Zhang W
Mol Cancer; 2023 Aug; 22(1):137. PubMed ID: 37582735
[TBL] [Abstract][Full Text] [Related]
27. Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer.
Liu Q
Front Genet; 2021; 12():825109. PubMed ID: 35087575
[TBL] [Abstract][Full Text] [Related]
28. N6-methyladenosine methylation in kidney injury.
Wang Q; Fan X; Sheng Q; Yang M; Zhou P; Lu S; Gao Y; Kong Z; Shen N; Lv Z; Wang R
Clin Epigenetics; 2023 Oct; 15(1):170. PubMed ID: 37865763
[TBL] [Abstract][Full Text] [Related]
29. The role of m6A methylation in therapy resistance in cancer.
Zhuang H; Yu B; Tao D; Xu X; Xu Y; Wang J; Jiao Y; Wang L
Mol Cancer; 2023 Jun; 22(1):91. PubMed ID: 37264402
[TBL] [Abstract][Full Text] [Related]
30. m6A modification of mRNA in skin diseases.
Yan Z; Liang P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 47(8):1154-1162. PubMed ID: 36097784
[TBL] [Abstract][Full Text] [Related]
31. The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma.
Chen F; Xie X; Chao M; Cao H; Wang L
Front Immunol; 2022; 13():917153. PubMed ID: 35711459
[TBL] [Abstract][Full Text] [Related]
32. The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development.
Liu S; Chen S; Tang C; Zhao Y; Cui W; Jia L; Wang L
Front Oncol; 2022; 12():970833. PubMed ID: 36226062
[TBL] [Abstract][Full Text] [Related]
33. N6-Methyladenosine Methylation Analysis of Long Noncoding RNAs and mRNAs in IPEC-J2 Cells Treated With
Yang J; Yang Q; Zhang J; Gao X; Luo R; Xie K; Wang W; Li J; Huang X; Yan Z; Wang P; Gun S
Front Immunol; 2021; 12():769204. PubMed ID: 34880865
[TBL] [Abstract][Full Text] [Related]
34. Methylation recognition protein YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) regulates the proliferation, migration and invasion of osteosarcoma by regulating m6A level of CCR4-NOT transcription complex subunit 7 (CNOT7).
Wei K; Gao Y; Wang B; Qu YX
Bioengineered; 2022 Mar; 13(3):5236-5250. PubMed ID: 35156522
[TBL] [Abstract][Full Text] [Related]
35. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
Front Immunol; 2021; 12():773570. PubMed ID: 34956201
[TBL] [Abstract][Full Text] [Related]
36. Epitranscriptomics: Correlation of N6-methyladenosine RNA methylation and pathway dysregulation in the hippocampus of HIV transgenic rats.
Fu Y; Zorman B; Sumazin P; Sanna PP; Repunte-Canonigo V
PLoS One; 2019; 14(1):e0203566. PubMed ID: 30653517
[TBL] [Abstract][Full Text] [Related]
37. Involvement of N6-methyladenosine modifications of long noncoding RNAs in systemic lupus erythematosus.
Wu J; Deng LJ; Xia YR; Leng RX; Fan YG; Pan HF; Ye DQ
Mol Immunol; 2022 Mar; 143():77-84. PubMed ID: 35051888
[TBL] [Abstract][Full Text] [Related]
38. Interactions between m6A modification and miRNAs in malignant tumors.
Han X; Guo J; Fan Z
Cell Death Dis; 2021 Jun; 12(6):598. PubMed ID: 34108450
[TBL] [Abstract][Full Text] [Related]
39. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
Li Z; Li F; Peng Y; Fang J; Zhou J
Cancer Med; 2020 Mar; 9(5):1877-1889. PubMed ID: 31943856
[TBL] [Abstract][Full Text] [Related]
40. Insights into N6-methyladenosine and programmed cell death in cancer.
Liu L; Li H; Hu D; Wang Y; Shao W; Zhong J; Yang S; Liu J; Zhang J
Mol Cancer; 2022 Jan; 21(1):32. PubMed ID: 35090469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
